Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 10, 2003, Pages 1319-1324

  Mandal, A ^a   Playford, R J ^b   Wicks, A C ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BARRETT ESOPHAGUS; CLINICAL PRACTICE; DYSPLASIA; ESOPHAGUS BIOPSY; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; HEALTH SURVEY; HUMAN; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED KINGDOM;

BARRETT ESOPHAGUS; ESOPHAGOSCOPY; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES; PROFESSIONAL PRACTICE; QUESTIONNAIRES;

EID: 0037944079     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01586.x     Document Type: Article

References (19)

1. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87: 927-33.
2. Cameron AJ, Ott J, Payne WS. The incidence of adenocarcinoma in columnar lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
3. Spechler SJ, Goyal RK. The columnar lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996; 110: 614-21.
4. Sampliner RE and The Practice Parameters Committee of the American College of Gastroenterology. Practice Guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028-32.
5. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8.
6. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2002; 97: 1888-95.
7. Dent J, Bremner CG, Collen MJ, et al. Working Party report to the World Congress of Gastroenterology, Sydney 1990. Barrett's oesophagus. J Gastroenterol Hepatol 1991; 6: 1-22.
8. Allum WH, Griffin SM, Watson A. et al. Guidelines for the management of gastric and oeosphageal cancer. Gut 2002; 50(Supph 5): 1-23.
9. Moghissi K, Sharpe DA, Pender D. Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study. Fur J Cardiothorac Surg 1993; 7: 126-31.
10. Lerut T, Coosemans W, Van Raemdonck D, et al. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg 1994; 107: 1059-65.
11. van der Burgh A, Dees J, Hop WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8.
12. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993; 72: 1155-8.
13. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-8.
14. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus. Ann Intern Med 2000; 132: 612-20.
15. Gross CP, Canto MI, Hixson J, Powe NR. Management of Barrett's esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol 1999; 94: 3440-7.
16. Reid BJ, Haggit RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's oesophagus. Human Pathol 1998; 19: 166-78.
17. Macdonald CE, Wicks AC, Playford RJ. Final results from ten year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. Br Med J 2000; 321: 1252-5.
18. Barr H. Protagonist: endoscopic surveillance for Barrett's oesophagus. Gut 2002; 51: 313.
19. Playford RJ. Antagonist: endoscopic surveillance of patients with Barrett's oesophagus. Gut 2002; 51: 314-5.